Clinical Trial Update: Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating safety and activity of GSK2857916 plus pembrolizumab in relapsed/refractory multiple myeloma has completed Phase 1/2 with posted resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• GSK2857916
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-12-23